Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 273

The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.

Current perspectives on selective dopamine D3receptor antagonists as pharmacotherapeutics for addictions and related disorders

Open access
Heidbreder, Christian A., Newman, Amy H. · 2010 · Annals of the New York Academy of Sciences

Abstract

Repeated exposure to drugs of abuse produces long‐term molecular and neurochemical changes that may explain the core features of addiction, such as the compulsive seeking and taking of the drug, as well as the risk of relapse. A growing number of new molecular and cellular targets of addictive drugs have been identified, and rapid advances are being made in relating those targets to specific behavioral phenotypes in animal models of addiction. In this context, the pattern of expression of the dopamine (DA) D 3 receptor in the rodent and human brain and changes in this pattern in response to drugs of abuse have contributed primarily to direct research efforts toward the development of selective DA D 3 receptor antagonists. Growing preclinical evidence indicates that these compounds may actually regulate the motivation to self‐administer drugs and disrupt drug‐associated cue‐induced craving. This report will be divided into three parts. First, preclinical evidence in support of the efficacy of selective DA D 3 receptor antagonists in animal models of drug addiction will be reviewed. The effects of mixed DA D 2/D 3 receptor antagonists will not be discussed here because most of these compounds have low selectivity at the D 3 versus D 2 receptor, and their efficacy profile is related primarily to functional antagonism at D 2 receptors and possibly interactions with other neurotransmitter systems. Second, major advances in medicinal chemistry for the identification and optimization of selective DA D 3 receptor antagonists and partial agonists will be analyzed. Third, translational research from preclinical efficacy studies to so‐called proof‐of‐concept studies for drug addiction indications will be discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2009.05149.x

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 183 references

Cited by

See all 273

Metadata

Authors
Heidbreder, C. A., & Newman, A. H.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2010-02
Volume
1187
Issue
1
Pages
4-34
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W1482965181
Cited by
273
References
183
FWCI
10.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current perspectives on selective dopamine D3receptor antagonists as pharmacotherapeutics for addictions and related disorders. https://app.cochat.ai/papers/10.1111/j.1749-6632.2009.05149.x
The paper
Heidbreder, C. A., & Newman, A. H. (2010). Current perspectives on selective dopamine D3receptor antagonists as pharmacotherapeutics for addictions and related disorders. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.05149.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.